-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
When the medical insurance department sets the payment standard for the drugs in the reimbursement catalog, drugs with multiple different indications often cause confusion
How to formulate the medical insurance payment standard:
Judging from international experience, some countries use differential pricing for different indications, while others use uniform pricing, and there is no certain rule
The reason why the pricing of multi-indication drugs can cause trouble is the following thinking path: the pricing of a new drug in a certain indication should consider the therapeutic effect of the drug for this indication, and its effect is better than other drugs in the indication The extent of this, and the price of other drugs
The reason why the pricing of multi-indication drugs is troublesome is because of the following thinking path:
The above thoughts are essentially pricing new drugs based on medical value
The above thoughts are essentially pricing new drugs based on medical value
Must we stick to the method of value pricing?
The value currently discussed is essentially a comparison of the utility of investing scarce resources here and elsewhere
The value currently discussed is essentially a comparison of the utility of investing scarce resources here and elsewhere
However, this is not the only standard for pricing, nor should it be the only standard for medical insurance to formulate payment standards
As a buyer, the payment standard established by medical insurance must be higher than the cost of the supplier, and there must be a certain profit margin, otherwise the supplier will not need to continue to supply, and can invest resources elsewhere to make profits
From the perspective of cost, regardless of the number of indications for the drug, the cost can be uniformly calculated for reasonable pricing